---
figid: PMC11582033__fonc-14-1504142-g007
figtitle: Combination therapy of melanoma using BRAF, MEK, and immune checkpoint inhibitors
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11582033
filename: fonc-14-1504142-g007.jpg
figlink: /pmc/articles/PMC11582033/figure/F7/
number: F7
caption: Combination therapy of melanoma using BRAF, MEK, and immune checkpoint inhibitors.
  (A) In melanoma, triple therapy integrates BRAFi, MEKi, and immune checkpoint inhibitors
  (ICI) to combat cancer cells via diverse pathways. BRAFi and MEKi disrupt cancer
  cell signaling, while ICI boosts the anticancer immune system. This strategy enhances
  treatment efficacy, overcomes resistance, and potentially elevates outcomes for
  advanced melanoma patients. (B) BRAF mutations in untreated melanoma shape distinct
  immune environments, marked by reduced CD8+ T cells and elevated CD4+ T cells. Metastatic
  BRAF-mutant melanomas display elevated CD4+ T and B cells but reduced CD8+ T cells
papertitle: 'The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles
  and unleashing novel strategies'
reftext: Saber Imani, et al. Front Oncol. 2024;14(NA).
year: '2024'
doi: 10.3389/fonc.2024.1504142
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media SA
keywords: melanoma | BRAF inhibitors | MEK inhibitors | targeted therapy | precision
  medicine
automl_pathway: 0.7468284
figid_alias: PMC11582033__F7
figtype: Figure
redirect_from: /figures/PMC11582033__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11582033__fonc-14-1504142-g007.html
  '@type': Dataset
  description: Combination therapy of melanoma using BRAF, MEK, and immune checkpoint
    inhibitors. (A) In melanoma, triple therapy integrates BRAFi, MEKi, and immune
    checkpoint inhibitors (ICI) to combat cancer cells via diverse pathways. BRAFi
    and MEKi disrupt cancer cell signaling, while ICI boosts the anticancer immune
    system. This strategy enhances treatment efficacy, overcomes resistance, and potentially
    elevates outcomes for advanced melanoma patients. (B) BRAF mutations in untreated
    melanoma shape distinct immune environments, marked by reduced CD8+ T cells and
    elevated CD4+ T cells. Metastatic BRAF-mutant melanomas display elevated CD4+
    T and B cells but reduced CD8+ T cells
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - CTLA4
  - CD274
  - CD80
  - CD86
  - NRAS
  - EPHB2
  - MAPK1
  - MAPK3
  - PDK1
  - PDPK1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - TH
  - CD4
  - CD8A
  - CD8B
  - MEK
  - Vemurafenib
  - Dabrafenib
  - Binimetinib
  - Cobimetinib
  - Trametinib
  - Melanoma
---
